This page shows the latest risdiplam news and features for those working in and with pharma, biotech and healthcare.
Roche has presented positive results from an ongoing study evaluating its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) in babies aged from birth to six weeks with pre-symptomatic disease.
Evrysdi (risdiplam), which is already authorised for use in patients aged two months or older, can now be used to treat infants from birth to below two months with a clinical
The new findings follow the recent roll-out of three new SMA medicines provided on the NHS: injectable drug Spinraza (nurinersen), gene therapy Zolgensma and oral treatment risdiplam, as well as
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the existing EU marketing authorisation for Evrysdi (risdiplam), which is approved to treat patients aged two months or older,
Roche has announced positive new four-year results from an open-label extension study of its spinal muscular atrophy (SMA) treatment, Evrysdi (risdiplam), in young children.
Genentech – a member of the Roche group – has announced new two-year data from its JEWELFISH study evaluating Evrysdi (risdiplam) in patients with type 1, 2 or 3 spinal muscular atrophy
More from news
Approximately 7 fully matching, plus 27 partially matching documents found.
No results were found
Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...